**What is claimed is:**

1. An isolated cell comprising a complex comprising a CRISPR from *Prevotella* and *Franciscella* 1 (Cpf1) RNA-guided nuclease and a gRNA comprising a targeting domain that is complementary to a sequence of a TRAC gene, wherein the gRNA is effective in generating one or more modifications in the TRAC gene, wherein the targeting domain comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 3535, SEQ ID NO: 3563, SEQ ID NO: 3514 and SEQ ID NO: 3451, wherein the targeting domain is 20, 21, 22, 23, 24 or 25 nucleotides in length.

2. The isolated cell of claim 1, wherein the targeting domain is 20 or 21 nucleotides in length.

3. The isolated cell of claim 1, wherein the targeting domain comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 3538, 3566, 3517 and 3454, wherein the targeting domain is 23, 24 or 25 nucleotides in length.

4. The isolated cell of any one of claims 1-3, wherein the isolated cell is:
   (a) a T cell;
   (b) a lymphoid progenitor cell;
   (c) a hematopoietic stem cell;
   (d) a natural killer cell (NK cell);
   (e) a dendritic cell; or
   (f) an induced pluripotent stem (iPS) cell or a cell derived from an iPS cell.

5. The isolated cell of claim 4, wherein the T cell is selected from the group consisting of a $CD8^+$ T cell, a central memory T cell, an effector memory T cell, a $CD4^+$ T cell, a natural killer T cell (NK T cell), a regulatory T cell (Treg) and a stem cell memory T cell.

6. The isolated cell of claim 5, wherein the T cell is a $CD8^+$ T cell.

7. The isolated cell of claim 6, wherein the $CD8^+$ T cell is a $CD8^+$ naïve T cell, a central memory T cell, or an effector memory T cell.

8. The isolated cell of any one of claims 1-7, wherein the cell is an engineered cell.



°°°°°

9. The isolated cell of claim 8, wherein the engineered cell is an engineered chimeric antigen receptor (CAR) T cell or an engineered TCR (T cell receptor) T cell.

10. An *ex vivo* method of modifying a cell, comprising contacting the cell with a composition comprising:

(a) a gRNA molecule comprising a targeting domain that is complementary to a sequence of a TRAC gene, wherein the gRNA is effective in generating one or more modifications in the TRAC gene; and

(b) a Cpf1 RNA-guided nuclease or a nucleic acid capable of expressing the Cpf1 RNA-guided nuclease in the cell,

wherein the targeting domain comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 3535, SEQ ID NO: 3563, SEQ ID NO: 3514 and SEQ ID NO: 3451, wherein the targeting domain is 20, 21, 22, 23, 24 or 25 nucleotides in length.

11. The method of claim 10, wherein the targeting domain is 20 or 21 nucleotides in length.

12. The method of claim 10, wherein the targeting domain comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 3538, 3566, 3517 and 3454, wherein the targeting domain is 23, 24 or 25 nucleotides in length.

13. The method of any one of claims 10-12, wherein said contacting comprises introducing the composition into the cell by electroporation.

14. The method of any one of claims 10-13, wherein the composition comprises a ribonucleoprotein (RNP) complex comprising the gRNA molecule and the Cpf1 RNA-guided nuclease.

15. The method of any one of claims 10-13, wherein the composition comprises the gRNA molecule and the nucleic acid capable of expressing the Cpf1 RNA-guided nuclease in the cell.

16. A population of isolated cells, wherein the cells comprise a complex comprising a Cpf1 RNA-guided nuclease and a gRNA molecule comprising a targeting domain that is complementary to a sequence of a TRAC gene, wherein the gRNA is effective in generating one or more modifications in the TRAC gene,

wherein the targeting domain comprises a nucleotide sequence selected from the group

consisting of SEQ ID NO: 3535, SEQ ID NO: 3563, SEQ ID NO: 3514 and SEQ ID NO: 3451, wherein the targeting domain is 20, 21, 22, 23, 24 or 25 nucleotides in length.

17. The population of claim 16, wherein the targeting domain is 20 or 21 nucleotides in length.

18. The population of claim 16, wherein the targeting domain comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 3538, 3566, 3517 and 3454, wherein the targeting domain is 23, 24 or 25 nucleotides in length.

19. The population of any one of claims 16-18, wherein the cells are selected from the group consisting of:

(a) T cells;

(b) lymphoid progenitor cells;

(c) hematopoietic stem cells;

(d) NK cells;

(e) dendritic cells; or

(f) iPS cells or cells derived from iPS cells.

20. The population of claim 19, wherein the T cells are selected from the group consisting of $CD8^+$ T cells, central memory T cells, effector memory T cells, $CD4^+$ T cells, NKT cells, regulatory T cells (Tregs) and stem cell memory T cells.

21. The population of claim 20, wherein the T cell is a $CD8^+$ T cell.

22. The population of claim 21, wherein the $CD8^+$ T cell is a $CD8^+$ naïve T cell, a central memory T cell, or an effector memory T cell.

23. The population of any one of claims 16-22, wherein the cells are engineered cells.

24. The population of claim 23, wherein the engineered cells are engineered chimeric antigen receptor (CAR) T cells or engineered TCR (T cell receptor) T cells.

25. An isolated modified immune cell comprising an RNP complex comprising a Cpf1 RNA-guided endonuclease and a gRNA comprising a targeting domain that is complementary to a nucleic acid sequence of a TRAC gene, wherein the gRNA is effective in generating one or more

modifications in the TRAC gene, wherein the targeting domain comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 3535, SEQ ID NO: 3563, SEQ ID NO: 3514 and SEQ ID NO: 3451, wherein the targeting domain is 20, 21, 22, 23, 24 or 25 nucleotides in length.

26. The isolated modified immune cell of claim 25, wherein the targeting domain is 20 or 21 nucleotides in length.

27. The isolated modified immune cell of claim 25, wherein the targeting domain comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 3538, 3566, 3517 and 3454, wherein the targeting domain is 23, 24 or 25 nucleotides in length.

28. The isolated modified immune cell of any one of claims 25-27, wherein the RNP complex is delivered into the immune cell via electroporation.



°°°°°